Recent Updates
Recently added Catalysts
CNTN Positive Sentiment Score: 70/100

Canton Strategic Holdings, Inc. Announces Sale of Gravitas Life Sciences, LLC

Key Takeaway: Canton Strategic Holdings, Inc. has announced the sale of its biotech arm, Gravitas Life Sciences, to Gravitas Collective Corp. This transaction, which closed on July 17, 2026, was unanimously approved by the Board of Directors. The sale allows the company to concentrate on its Canton Network strategy aimed at digitizing traditional financial markets.

Market Sentiment Analysis

POSITIVE FACTORS

  • Successful sale of Gravitas Life Sciences enhances focus on core strategy.
  • Transaction aligns with the company's transition to digitizing financial markets.
  • Unanimous approval from the Board of Directors indicates strong internal support.

Full Press Release Details

Transaction Drives Greater Focus on Company's Canton Network Strategy
NEW YORK,July 23, 2026/PRNewswire/ -- Canton Strategic Holdings, Inc., (NASDAQ:CNTN) ("Canton Strategic Holdings" or the "Company") the first publicly traded company to leverage Canton Coin to support the Canton Network's ability to digitize traditional financial markets, today announced the sale of its biotech research and development arm, Gravitas Life Sciences, LLC ("Gravitas"), to Gravitas Collective Corp. The transaction was approved unanimously by the Board of Directors and closed on July 17, 2026.
This milestone aligns with the Company's transition to an operating company that drives the digitization of financial markets via the Canton Network and builds on recent progress in its operating business, including its locking service launch in June 2026.

About Canton Strategic Holdings, Inc.

Canton Strategic Holdings, Inc. (NASDAQ:CNTN), is the first publicly traded company to leverage Canton Coin and support the Canton Network to advance institutional blockchain adoption and the digitization of financial markets. In addition to its operating business that drives value through activities on the Canton Network, the Company is a strategic investor in the Canton ecosystem. For more information, visitwww.cantonstrategic.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that constitute "forward-looking statements" within the meaning of U.S. federal securities laws. Forward-looking statements are statements other than historical facts and include, without limitation, those regarding management expectations, strategy execution, market conditions, and the Company's involvement with the Canton Network. These statements are based on current expectations and involve risks and uncertainties that may cause actual results to differ materially. Further information regarding factors that may affect the Company's prospects is included in its annual and quarterly reports filed with the U.S. Securities and Exchange Commission, available atwww.sec.gov. The Company undertakes no obligation to update these statements except as required by law.
Canton is a registered trademark of Digital Asset (Switzerland) GmbH. Digital Asset is not affiliated with, and has not sponsored or endorsed, the operations of Canton Strategic Holdings, Inc.

ContactsMedia:Gasthalter & Co.(212) 257-4170[email protected]

Investors:[email protected]

Frequently Asked Questions

What company did Canton Strategic Holdings sell?

Canton Strategic Holdings sold its biotech arm, Gravitas Life Sciences, LLC.

When did the sale of Gravitas Life Sciences close?

The sale closed on July 17, 2026.

What is the focus of Canton Strategic Holdings after the sale?

The company aims to focus on digitizing traditional financial markets through the Canton Network.

Who approved the sale of Gravitas Life Sciences?

The sale was unanimously approved by the Board of Directors.

Last updated: Jul 23, 2026